Publicacións en colaboración con investigadores/as de Vita-Salute San Raffaele University (23)

2024

  1. Erratum: Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome medicine (2023) 15 1 (22))

    Genome medicine

  2. Individual Prognostication of Disease Activity and Disability Worsening in Multiple Sclerosis With Retinal Layer Thickness z Scores

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 11, Núm. 5

  3. Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review

    Frontiers in Immunology, Vol. 15

  4. Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

    HemaSphere

  5. Wiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival

    Blood, Vol. 143, Núm. 24, pp. 2504-2516

2023

  1. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity

    Journal of Allergy and Clinical Immunology, Vol. 152, Núm. 4, pp. 984-996.e10

  2. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

    Leukemia, Vol. 37, Núm. 7, pp. 1521-1529

  3. European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

    European Journal of Neurology, Vol. 30, Núm. 8, pp. 2144-2176

  4. Prediction of Nonrelapse Mortality in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation with Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis

    HemaSphere

  5. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

    Genome Medicine, Vol. 15, Núm. 1

  6. Scalable GMP-compliant gene correction of CD4+ T cells with IDLV template functionally validated in vitro and in vivo

    Molecular Therapy - Methods and Clinical Development, Vol. 30, pp. 546-557

  7. Unbiased assessment of genome integrity and purging of adverse outcomes at the target locus upon editing of CD4+ T-cells for the treatment of Hyper IgM1

    EMBO Journal, Vol. 42, Núm. 23

2022

  1. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

    Multiple Sclerosis Journal, Vol. 28, Núm. 5, pp. 842-846

  2. Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4](S2152265021X00122)

    Clinical Lymphoma, Myeloma and Leukemia

2021

  1. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study

    Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 2, pp. 520-531

  2. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus

    Journal of Neurology, Vol. 268, Núm. 11, pp. 3961-3968

  3. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

    European Journal of Immunology, Vol. 51, Núm. 12, pp. 2708-3145

  4. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

    Science immunology, Vol. 6, Núm. 62

2020

  1. Ascend: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia

    Journal of Clinical Oncology

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy